» Articles » PMID: 37274187

As a Model to Study Autophagy in Neurodegenerative Diseases Induced by Proteinopathies

Overview
Journal Front Neurosci
Date 2023 Jun 5
PMID 37274187
Authors
Affiliations
Soon will be listed here.
Abstract

Proteinopathies are a large group of neurodegenerative diseases caused by both genetic and sporadic mutations in particular genes which can lead to alterations of the protein structure and to the formation of aggregates, especially toxic for neurons. Autophagy is a key mechanism for clearing those aggregates and its function has been strongly associated with the ubiquitin-proteasome system (UPS), hence mutations in both pathways have been associated with the onset of neurodegenerative diseases, particularly those induced by protein misfolding and accumulation of aggregates. Many crucial discoveries regarding the molecular and cellular events underlying the role of autophagy in these diseases have come from studies using Drosophila models. Indeed, despite the physiological and morphological differences between the fly and the human brain, most of the biochemical and molecular aspects regulating protein homeostasis, including autophagy, are conserved between the two species.In this review, we will provide an overview of the most common neurodegenerative proteinopathies, which include PolyQ diseases (Huntington's disease, Spinocerebellar ataxia 1, 2, and 3), Amyotrophic Lateral Sclerosis (C9orf72, SOD1, TDP-43, FUS), Alzheimer's disease (APP, Tau) Parkinson's disease (a-syn, parkin and PINK1, LRRK2) and prion diseases, highlighting the studies using Drosophila that have contributed to understanding the conserved mechanisms and elucidating the role of autophagy in these diseases.

Citing Articles

Emerging roles of antimicrobial peptides in innate immunity, neuronal function, and neurodegeneration.

Lee S, Silverman N, Gao F Trends Neurosci. 2024; 47(11):949-961.

PMID: 39389804 PMC: 11563872. DOI: 10.1016/j.tins.2024.09.001.


GABA-transaminase: A Key Player and Potential Therapeutic Target for Neurological Disorders.

Grover S, Narang R, Singh S Cent Nerv Syst Agents Med Chem. 2024; 24(1):57-67.

PMID: 38243961 DOI: 10.2174/0118715249267700231116053516.


Senolytic and senomorphic secondary metabolites as therapeutic agents in models of Parkinson's disease.

Miller S, Darji R, Walaieh S, Lewis J, Logan R Front Neurol. 2023; 14:1271941.

PMID: 37840914 PMC: 10568035. DOI: 10.3389/fneur.2023.1271941.


Intrinsic determinants of prion protein neurotoxicity in : from sequence to (dys)function.

Cembran A, Fernandez-Funez P Front Mol Neurosci. 2023; 16:1231079.

PMID: 37645703 PMC: 10461008. DOI: 10.3389/fnmol.2023.1231079.

References
1.
Lashuel H, Overk C, Oueslati A, Masliah E . The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci. 2012; 14(1):38-48. PMC: 4295774. DOI: 10.1038/nrn3406. View

2.
Li Z, Karlovich C, Fish M, Scott M, Myers R . A putative Drosophila homolog of the Huntington's disease gene. Hum Mol Genet. 1999; 8(9):1807-15. DOI: 10.1093/hmg/8.9.1807. View

3.
Beckers J, Tharkeshwar A, Van Damme P . C9orf72 ALS-FTD: recent evidence for dysregulation of the autophagy-lysosome pathway at multiple levels. Autophagy. 2021; 17(11):3306-3322. PMC: 8632097. DOI: 10.1080/15548627.2021.1872189. View

4.
Min B, Kwon Y, Choe K, Chung K . PINK1 phosphorylates transglutaminase 2 and blocks its proteasomal degradation. J Neurosci Res. 2015; 93(5):722-35. DOI: 10.1002/jnr.23535. View

5.
Ugolino J, Ji Y, Conchina K, Chu J, Nirujogi R, Pandey A . Loss of C9orf72 Enhances Autophagic Activity via Deregulated mTOR and TFEB Signaling. PLoS Genet. 2016; 12(11):e1006443. PMC: 5119725. DOI: 10.1371/journal.pgen.1006443. View